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Calcitonin Gene-Related Peptide–Expressing Sensory Neurons
and Spinal Microglial Reactivity Contribute to Pain States in
Collagen-Induced Arthritis
Francisco R. Nieto,1 Anna K. Clark,1 John Grist,1 Victoria Chapman,2
and Marzia Malcangio1
Objective. To evaluate the contribution of sensory
neurons in ankle joints and adjacent tissue to the devel-
opment of pain in collagen-induced arthritis (CIA), and
to determine the relationship between pain and the
appearance of clinical signs.
Methods. Mechanical and heat hypersensitivity
and hind paw swelling were assessed in Lewis rats before
and until 18 days following collagen immunization. We
examined the effect of intrathecal administration of a
calcitonin gene-related peptide (CGRP) antagonist
(CGRP8–37) from day 11 to day 18 postimmunization on
CIA-induced hypersensitivity. During CIA development,
CGRP and p-ERK immunoreactivity was quantified in
lumbar dorsal root ganglia in which sensory neurons
innervating the ankle joint were identified by retrograde
labeling with Fluoro-Gold. Microgliosis in the lumbar
dorsal horn was assessed by immunohistochemistry, and
release of CGRP evoked by activity of primary afferent
fibers was measured using a preparation of isolated dor-
sal horn with dorsal roots attached.
Results. CIA was associated with mechanical
hypersensitivity that was evident before hind paw swelling
and that was exacerbated with the development of swel-
ling. Heat hyperalgesia developed along with swelling.
Concomitant with the development of mechanical hyper-
sensitivity, joint innervating neurons exhibited enhanced
CGRP expression and an activated phenotype (increased
p-ERK expression), and significant microgliosis became
evident in the dorsal horn; these peripheral and central
changes were augmented further with disease progres-
sion. CGRP release evoked by dorsal root stimulation was
higher in the dorsal horn on day 18 in rats with CIA com-
pared to control rats. Prolonged intrathecal administra-
tion of CGRP8–37 attenuated established mechanical
hypersensitivity and reduced spinal microgliosis.
Conclusion. Sensory neuron–derived CGRP sus-
tains mechanical hypersensitivity and spinal microglial
reactivity in CIA, suggesting that central mechanisms
play critical roles in chronic inflammatory pain. Block-
ade of these central events may provide pain relief in
rheumatoid arthritis patients.
Pain is the most dominant and impairing symp-
tom associated with rheumatoid arthritis (RA).
Patients may experience pain before clinical signs per-
mit confirmation of the diagnosis of RA (1); thus, pain
is present at the predisease stage as well as during the
disease stage of RA. Treatment of RA pain with non-
steroidal antiinflammatory drugs (NSAIDs) results in
modest efficacy and may produce side effects (2).
Improved understanding of the specific mechanisms of
RA-associated pain will enable us to identify new strat-
egies for analgesia.
Collagen-induced arthritis (CIA) is a clinically
relevant model of RA. The immunopathogenesis of
CIA involves both B and T lymphocyte responses, with
the production of type II collagen–specific antibodies
that bind to cartilage in the joints (3). The resulting
pathogenesis shares several pathologic features with
RA, including synovial hyperplasia, inflammatory cell
infiltration, and cartilage degradation (3). However,
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only a few studies (by our group and others) have
investigated the mechanisms underlying pain in this
model in either mice (4) or rats (5).
Although cartilage is not innervated, inflammation
of the synovial membrane and bone alterations can lead
to the sensitization of primary afferent fibers (nocicep-
tors) that innervate the joints and tissue outside the joints
(peripheral sensitization) and respond to noxious stimuli
(6). All nociceptors contain glutamate, while the pepti-
dergic subpopulation of nociceptors also contains sub-
stance P (SP) and calcitonin gene-related peptide
(CGRP) (7,8) and is especially enriched in the joint (9).
Increased input from such sensitized afferent fibers,
whose cell bodies are located in the dorsal root ganglia
(DRGs), can lead to an augmented release of glutamate,
SP, and CGRP from their central terminals in the spinal
cord (10), whereby increased activation of specific recep-
tors in dorsal horn neurons results in amplification of sig-
naling (central sensitization) (6). Along with neurons,
spinal microglia are known to respond to increased neu-
ronal activity and play modulatory roles by releasing pro-
nociceptive mediators (11–14). Central sensitization can
contribute to secondary hyperalgesia in joint-adjacent tis-
sue (hind paw), as many spinal cord neurons receive con-
vergent inputs from skin and deep tissues (6,13).
Our recent work demonstrated that the early
stages of CIA are associated with increased nocifensive
behavior prior to the appearance of clinical signs of the
disease, whereas at later stages nocifensive responses are
present concomitant with significant hind paw swelling
and enhanced spinal microglial response (5). The weak
correlation between pain and swelling in the early stages
of CIA mimics the clinical situation (1) and suggests that
mechanisms other than overt inflammation contribute to
pain at this stage. Thus, in this study we evaluated
whether nociceptive sensory neurons innervating the joint
and adjacent tissues are recruited and activated during
the development of pain and inflammation in CIA and
contribute to associated spinal mechanisms.
MATERIALS AND METHODS
Animals. Experiments were performed in 70 female
adult Lewis rats weighing 180–200 gm (Charles River UK).
Experimental study groups were randomized, and assessments
were performed under blinded conditions. All experiments
were undertaken with approval of the UK Home Office.
CIA. As described previously (5), 4 mg/ml bovine type
II collagen (MD Bioproducts) was dissolved in 0.1M acetic
acid and emulsified with 1 mg/ml Freund’s complete adjuvant
(CFA; BD Biosciences). Rats were anesthetized with isoflur-
ane (Abbott) and injected intradermally at the base of the tail
with 400 mg collagen/200 ml CFA or 200 ml CFA emulsion
(control rats).
Macroscopic assessment of arthritis. Rats were
scored on a scale of 0–3 per hind paw (0–6 per rat) (5). Ankle
swelling, the earliest visible sign of arthritis, was scored as 1.
Thereafter, footpad swelling occurred and was scored as 2.
Subsequent swelling of 1 or more digits resulted in a score of
3. The thickness of each hind paw was measured using a
thickness gauge (Mitutoyo) and expressed in mm. Clinical
signs of arthritis and body weight were monitored prior to
immunization and then throughout the disease process.
Behavior indicating pain. Mechanical and thermal
hypersensitivity in the hind paws was assessed as an indicator
of secondary hyperalgesia remote from the inflamed ankle
joint. Changes in hind paw mechanical withdrawal thresholds
were assessed by applying a series of calibrated von Frey fila-
ments (0.4–15 gm; North Coast Medical) to the plantar sur-
face of the hind paw according to the “up-down” method
(15). On each day of testing, animals were habituated for 15
minutes in individual transparent Plexiglas boxes with a wire
mesh bottom in a temperature-controlled room (22C). Cali-
brated von Frey filaments were applied to the plantar surface
of the hind paw for 3–5 seconds or until the paw was with-
drawn. Mechanical thresholds of the left and right paws were
assessed alternately. Each test started with application of the
2-gm filament. Once a withdrawal response to a von Frey
hair was established, the paw was retested starting with the
filament below the one that elicited a withdrawal and subse-
quently with the remaining filaments in descending force
sequence until no withdrawal occurred and then in ascending
force sequence until a response was observed. This up-down
method was continued until the “k” value could be calculated
(between 4 and 9 applications of the von Frey hairs). From
this value, 50% withdrawal thresholds were calculated.
Heat hyperalgesia was assessed with a Plantar test
apparatus (Ugo Basile) as previously described (16). Rats were
habituated for 15 minutes to individual Plexiglas chambers
placed on a glass floor in a temperature-controlled room
(22C). A beam of radiant heat was applied onto the plantar
surface of each hind paw, and paw withdrawal latencies were
recorded. Withdrawal latencies were monitored 3 times in each
paw alternately, and the latencies of both paws were averaged
on each measurement day. At least 1 minute was allowed
between consecutive measurements in the same paw, and a cut-
off latency time of 20 seconds was used to avoid tissue damage.
Baseline measurements were obtained prior to collagen immu-
nization, and withdrawal latencies were then recorded on sev-
eral days throughout the disease process.
Intrathecal drug treatment. Two weeks prior to col-
lagen immunization, intrathecal cannulae were implanted at
the lumbar level in the spinal cord. While animals were under
anesthesia, a small laminectomy was performed at the sixth
thoracic vertebra and a flexible cannula was inserted under the
dura mater and glued in place, such that the tip rested at the
lumbar enlargement. The opposite end of the cannula was
placed subcutaneously, and 11 days after immunization an
osmotic minipump (Alzet model 2001) was connected to the
cannula (5). CGRP receptor antagonist CGRP8–37 (1 mg/ml;
Bachem) was delivered at 24 ml/day for 7 days (from day 11 to
day 18 postimmunization), resulting in a dose of 24 mg/day as
reported previously (17).
Histology. Ankle joints were excised from rats with
CIA and control rats that were perfuse-fixed on days 7 and
18 postimmunization. The joints were postfixed for 1 week in
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the perfusion fixative, decalcified for 3 days in 10% formic
acid with 0.5M trisodium citrate, and embedded in paraffin.
Longitudinal sections (7 mm) were cut from the center of the
ankle joint in the sagittal plane and stained with hematoxylin
and eosin. Sections were examined under light microscopy
for cellular infiltration, synovitis, and structural integrity.
Retrograde neuronal labeling. To identify the cell
bodies of ankle joint afferent neurons, 5 ml of 2% Fluoro-Gold
(FG; Fluorochrome) was injected intraarticularly using a Ham-
ilton syringe into the ankle joint of the rats 7 days prior to the
isolation of DRGs, as previously described (18). As intraarticu-
lar injection of FG does not produce bilateral labeling and
collagen immunization affects both joints, we performed intra-
articular injections of Fluoro-Gold in both ankle joints.
Tissue processing. On days 4, 7, and 18 postimmuni-
zation, naive rats, rats with CIA, and control rats were anes-
thetized with pentobarbital and transcardially perfused with
0.9% saline solution followed by 4% paraformaldehyde with
1.5% picric acid in 0.1M phosphate buffer (pH 7.4). L4 and
L5 DRGs and lumbar spinal cords were excised, postfixed for
4 hours in the perfusion fixative (4C), cryoprotected in 20%
sucrose in phosphate buffer (0.1M, 4C) for 48 hours, and
frozen in OCT embedding compound (VWR International).
DRG (15 mm) and spinal cord (20 mm) sections were
cryostat-cut and thaw-mounted onto Superfrost Plus micro-
scope slides (VWR International). In preliminary experi-
ments all lumbar DRGs (L1–L6) were excised from naive
rats and processed in the same way in order to elucidate the
segmental distribution of DRG neurons innervating the ankle
joint.
Immunohistochemistry. Slides containing every sixth
section of L4 and L5 DRGs from rats previously injected or
not injected with FG were blocked with 1% normal goat
serum (Jackson ImmunoResearch) for 1 hour and then incu-
bated overnight with solutions of primary antibodies (sheep
anti-CGRP [1:800; Enzo], monoclonal rabbit anti–phospho-
p44/42 MAPK [ERK-1/2] [p-ERK] [1:400; Cell Signaling
Technology], and/or Anti-bIII Tubulin monoclonal antibody
[1:1,000; Promega]) followed by incubation for 2 hours with
solutions of appropriate secondary antibodies (Alexa Fluor
350 or Alexa Fluor 488 conjugated [Molecular Probes] or
Cy3 conjugated [Jackson ImmunoResearch]). To ensure that
the intraarticular injection of FG was correctly located, some
FG-labeled sections from each injected rat were incubated
with fluorescein isothiocyanate–conjugated isolectin B4 (10
mg/ml; Sigma) for 1 hour, as it has been described that isolec-
tin B4 staining is absent or expressed at very low levels in
DRG neurons innervating joints (18–20). All antibodies were
prepared in phosphate buffered saline (PBS) with 0.5% nor-
mal goat serum and 0.1% Triton X-100 (Sigma).
Slides containing every sixth section of lumbar (L4 and
L5) spinal cord were incubated overnight with a solution of
the primary antibody rabbit anti–ionized calcium–binding
adapter molecule 1 (anti–IBA-1) (1:1,000; Wako) followed by
incubation for 2 hours with a solution of the appropriate sec-
ondary antibody (Alexa Fluor 488 conjugated). All antibodies
were prepared in PBS with 0.1% Triton X-100.
In control experiments, primary antibody was omitted
from some sections of spinal cords and DRGs; this resulted in
complete abolition of staining. Slides were coverslipped with
Vectashield mounting medium (Vector), and images were cap-
tured using a Zeiss Axioplan 2 fluorescence microscope.
Immunofluorescence analysis. FG-labeled DRG neu-
rons were easily identifiable and considered to be FG labeled
when cell profiles were clearly distinguishable from the faint,
homogeneous staining of unlabeled neurons. To study the
entire neuronal population in DRGs, sections not labeled with
FG were used and neurons were identified by the specific neu-
ronal marker bIII Tubulin. The number of FG-labeled or bIII
Tubulin–labeled neurons immunoreactive for CGRP and p-ERK
was counted (8–12 sections per rat and 4 sections per rat, respec-
tively) and expressed as the percentage of total FG-labeled or
bIII Tubulin–labeled neurons. In spinal cord sections, IBA-11
profiles (as indicative of the number of microglial cells) were
counted within fixed areas (6 in total) of 203 104mm2 on the lat-
eral, central, and medial dorsal horns (3 sections per rat) (5,21).
Bilateral DRGs and dorsal horns were included in the analysis,
and data were averaged for each rat.
Release of CGRP from dorsal horn slices. On day 7
or day 18 postimmunization, horizontal lumbar dorsal horn
slices (400 mm thick) with dorsal roots attached were obtained
from the lumbar spinal cord of rats as previously described
(22). One slice was obtained from each rat, mounted in the
central compartment of a 3-compartment chamber, and contin-
uously superfused (1 ml/minute) with oxygenated Krebs solution
(118 moles/liter NaCl, 4 moles/liter KCl, 1.2 moles/liter MgSO4,
1.2 moles/liter KH2PO4, 25 moles/liter NaHCO3, 2.5 moles/liter
CaCl2, and 11 moles/liter glucose) containing 0.1% bovine
serum albumin and 20 mg/ml bacitracin to minimize peptide
degradation. The dorsal roots were placed in the lateral com-
partments and immersed in mineral oil to avoid dehydration.
Before, during, and after electrical stimulation, 8-ml fractions of
superfusates were collected at 8-minute intervals from the cen-
tral compartment in glass tubes containing 0.1M acetic acid
(VWR International). The release of CGRP was evoked by
electrical stimulation of the dorsal roots for 8 minutes under
conditions mimicking the transmission of noxious stimuli (C
fiber strength; 20V, 0.5 msec, 10 Hz). Three 8-ml fractions were
collected before stimulation, one 8-ml fraction was collected
during electrical stimulation. and four 8-ml recovery fractions
were collected after stimulation.
To quantify CGRP content, superfusate samples were
partially purified and desalted using Sep-pak C18 reverse-phase
silica gel cartridges (Waters) previously conditioned with acetoni-
trile (VWR International) and 0.1% trifluoroacetic acid (TFA;
VWR International). The peptide was then eluted from columns
using a solution of acetonitrile/TFA (80:20). Eluates were dried
by evaporation under nitrogen, reconstituted in 300 ml of sample
buffer, and assayed for CGRP content by enzyme-linked immu-
nosorbent assay (standards 3.9–500 pg; SPI Bio). Data are
expressed as the percentage of CGRP content in basal fractions.
Statistical analysis. Differences between values in
behavioral tests were analyzed with two-way repeated-meas-
ures analysis of variance (ANOVA) followed by Tukey’s test.
Immunohistochemistry and release data were analyzed by
two-way ANOVA followed by Tukey’s test or by Student’s
t-test as appropriate. Data are reported as the mean6 SEM.
Differences between means were considered statistically sig-
nificant when P values were less than 0.05.
RESULTS
While both clinical scores and paw swelling
were apparent beginning 12–14 days after collagen
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immunization (Figure 1A), hind paw mechanical
thresholds decreased significantly on day 7 postimmu-
nization, decreasing further concomitant with establish-
ment of clinical signs (days 14–18) (Figure 1B). Hind
paw thermal thresholds decreased alongside the
appearance of clinical signs (days 14–18) (Figure 1B).
Histologic examination of the ankle joint revealed infil-
tration of inflammatory cells on day 7, which was exa-
cerbated by day 18 (Figures 1C and D).
We hypothesized that increasing recruitment of
sensory afferent fibers, which would be activated at the
site of inflammation in the ankle joints and the hind
paws, might contribute to the escalation of mechanical
and thermal hypersensitivity associated with CIA. The
numbers of neuronal cell bodies from the ankle joint
retrograde-labeled with Fluoro-Gold (FG1) were quan-
tified in naive rats, control (CFA emulsion–injected)
rats, and rats with CIA. In naive rats, ;85% of
retrograde-labeled neuronal cell bodies from the ankle
joint were in the L4 and L5 DRGs, and the remaining
15% were in L3 DRGs (Figures 2A and B). FG1 neu-
rons represented a mean 6 SEM of 2 6 0.4% and
46 0.3% of the total population of L4 and L5 neurons
(n5 6 rats), respectively. In rats with CIA, the number
of FG1 neurons in the L4 and L5 DRGs on days 4, 7,
and 18 following collagen immunization was similar to
the number in naive rats and control rats (Figure 2C).
In DRGs from naive rats, 60% of FG1 neurons had
small-size cell bodies, while 29% had medium-size cell
bodies and 9% had large-size cell bodies (Figure 2D).
This cell size distribution was not altered by CIA (Fig-
ure 2D). Thus, the majority of sensory neurons innervat-
ing the ankle joint were derived from the L4 and L5
DRGs and represented a small group of DRG neurons
that remained unaltered by the progression of CIA.
To investigate further the population of neurons
innervating the ankle joint and the impact of CIA on
them, expression of CGRP and p-ERK, as markers for
nociceptive neurons and neuronal activity, respectively,
was quantified in FG-labeled neurons and in the entire
L4 and L5 DRG neuronal population (innervating sites
outside the joint). At the earliest time point (day 4), there
was no difference in the number of FG1 neurons that
expressed CGRP in DRGs from naive or control rats or
rats with CIA (Figure 3A). By day 7 following collagen
immunization, there was a significant increase in the
number of FG1CGRP1 DRG neurons compared to
controls (Figure 3A). This increase in CGRP expression
remained significant on day 18 following injection of col-
lagen (Figures 3A and B). When the DRG neuronal
population was considered as a whole (sensory neurons
innervating both ankle and non-ankle joints), the number
of CGRP1 neurons was unaltered on days 4 and 7 fol-
lowing collagen immunization (Figure 3C), but was signif-
icantly increased on day 18 compared to controls
(Figures 3C and D). Nonpeptidergic isolectin B4–positive
neurons represented only 4.16 0.9% of FG1 neurons
Figure 1. Collagen-induced arthritis (CIA) is associated with devel-
opment of hind paw inflammation and behavior indicating pain. A,
Clinical scores and hind paw thickness. B, Hind paw mechanical and
thermal thresholds. C and D, Photomicrographs of hematoxylin and
eosin–stained ankle joints (C) and synovium (D). Values are the
mean6 SEM (8–12 rats per group). *5P, 0.05; **5P, 0.01;
***5P, 0.001 versus controls, by two-way repeated-measures ana-
lysis of variance followed by Tukey’s test. Bars5 100 mm. PWT 5
paw withdrawal threshold; PWLT5 paw withdrawal latency time.
SENSORY NEURONS AND MICROGLIA CONTRIBUTE TO PAIN IN CIA 1671
(mean 6 SEM) in naive DRGs (n5 4 rats) and
remained unaltered in DRGs obtained 4, 7, and 18 days
after collagen immunization (5.16 1.0%, 7.16 2.0%, and
6.56 1.3%, respectively; n5 4 rats per group).
We also quantified the expression of p-ERK in
FG1 and FG1CGRP1 neurons. On day 4, there were no
differences in p-ERK expression in FG1 neurons among
the 3 groups of rats (Figure 4A). By day 7, both FG1 and
Figure 2. Development of collagen-induced arthritis (CIA) induces no changes in numbers of ankle joint dorsal root ganglion (DRG) neurons
retrograde-labeled with Fluoro-Gold (FG1). A, FG1 neurons detected in ipsilateral (right) but not contralateral (left) L5 naive rat DRGs.
Bar5 100 mm. B, Distribution of FG1 neurons in naive rat L1–L6 DRGs (n5 6 rats). Circles represent individual values for each rat; horizontal
lines indicate the mean. C and D, Number (C) and cell size distribution (D) of FG1 neurons in L4 and L5 DRGs during CIA development
(n5 6 rats per group). Small size5 0–600 mm2; medium size5 600–1,200 mm2; large size5.1,200 mm2. Values are the mean6 SEM.
Figure 3. Development of CIA is associated with an increase in calcitonin gene-related peptide (CGRP)–expressing neurons in lumbar DRGs.
A, Quantification of CGRP1FG1 L4 and L5 DRG neurons during CIA development (n5 4–6 rats per group). B, CGRP1 neurons in L5
DRGs retrograde-labeled with FG in control rats and rats with CIA at 18 days. Arrows indicate FG1CGRP1 neurons; arrowheads indicate
FG1 neurons; chevrons indicate CGRP1 neurons. C, Quantification of CGRP1 neurons in whole L4 and L5 DRGs during CIA development
(n5 4 rats per group). D, CGRP1 neurons in control rats and rats with CIA at 18 days. Values are the mean6 SEM. **5P, 0.01;
***5P, 0.001 versus controls, by two-way analysis of variance followed by Tukey’s test. Bars5 100 mm. See Figure 2 for other definitions.
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FG1CGRP1 neurons showed a significant increase in p-
ERK expression, which was further increased on day 18
following collagen immunization (Figures 4A and C).
When the whole neuronal population in L4 and L5 DRGs
was considered, there was a significant increase in p-ERK
expression in neurons on both day 7 and day 18 following
collagen immunization (Figures 4B and D). However, p-
ERK expression in FG1CGRP1 neurons reached signifi-
cance only on day 18 following collagen immunization
compared to controls (Figure 4B).
These data indicate that beginning 7 days from
collagen immunization, CGRP-expressing sensory neu-
rons start to be activated in the ankle joint. Activation
of ankle joint afferents is then followed by activation of
neurons that innervate tissues outside the joints with
progression of CIA. As CGRP is a marker of nocicep-
tors, these data provide a correlation between sensory
neuron phenotype and increased nocifensive behavior
on both day 7 and day 18 of CIA.
In order to establish whether nociceptor activa-
tion in CIA resulted in increased input from the central
terminals of these neurons in the spinal cord, we quan-
tified the release of CGRP evoked by activity of pri-
mary afferent fibers. In the preparation of isolated
dorsal horn with dorsal roots attached, obtained from
control rats and from rats 7 and 18 days following col-
lagen immunization, CGRP levels in dorsal horn super-
fusates were significantly increased following electrical
stimulation of primary afferent fibers at noxious inten-
sity, returning to basal levels after stimulation (Figure
5A). However, CGRP release in dorsal horns from rats
with CIA at 18 days was significantly higher than that
in dorsal horns from control rats at 18 days and from
rats with CIA at 7 days (Figure 5A). Thus, despite the
increase in retrograde-labeled p-ERK1CGRP1 neu-
rons from the ankle of rats with CIA at 7 days, activity-
induced release of CGRP from their central terminals
in the dorsal horn remained at control levels. Indeed,
for enhanced activity-evoked release of CGRP from
the central terminals of nociceptors to occur, as was
evident 18 days following induction of CIA, not only
joint afferents but also neurons innervating tissues out-
side the joints must be recruited. In a further attempt
to determine signs of enhanced central activity 7 days
following collagen injection, we examined spinal micro-
glia and observed significant microgliosis in dorsal
Figure 4. CIA development is associated with increased p-ERK in lumbar DRGs. A, Quantification of FG1p-ERK1 neurons and FG1 calcito-
nin gene-related peptide–positive (CGRP1) p-ERK1 neurons in L4 and L5 DRGs during CIA development. B, Quantification of p-ERK1
neurons and p-ERK1CGRP1 neurons in the whole neuronal population in L4 and L5 DRGs during CIA development. In A and B, n5 4–6
rats per group. C, Phospho-ERK1 and CGRP1 neurons in L5 DRGs retrograde-labeled with FG in control rats and rats with CIA at 18 days.
Arrows indicate FG1p-ERK1CGRP1 neurons; arrowheads indicate FG1CGRP1 neurons; chevrons indicate CGRP1p-ERK1 neurons. D,
Phospho-ERK1 and CGRP1 neurons in the whole neuronal population in L4 and L5 DRGs in control rats and rats with CIA at 18 days. Val-
ues are the mean6 SEM. **5P, 0.01; ***5P, 0.001 versus controls, by two-way analysis of variance followed by Tukey’s test. Bars5 100
mm. See Figure 2 for other definitions.
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horns from rats with CIA compared to those from con-
trol rats at 7 days (Figure 5B), with further enhance-
ment in dorsal horns from rats with CIA at 18 days
(Figure 5B).
Finally, in order to evaluate whether increased
CGRP release from primary afferent fibers in the dorsal
horn contributed to mechanical hypersensitivity and
microgliosis, we intrathecally delivered a CGRP antago-
nist between days 11 and 18 of CIA. CGRP8–37 signifi-
cantly attenuated mechanical hypersensitivity (Figure
6A) but not thermal hypersensitivity (Figure 6B) and
produced a significant attenuation of microgliosis in the
dorsal horn (Figure 6C).
DISCUSSION
The main findings of this study are that before
the appearance of overt clinical signs of CIA, mechanical
Figure 5. Enhanced release of calcitonin gene-related peptide (CGRP) and significant microgliosis in the dorsal horn during collagen-induced
arthritis (CIA). A, Activity-evoked release of CGRP from primary afferent fibers in the dorsal horn of control rats at 18 days and rats with CIA
at 7 days and 18 days (n5 7 rats per group). Mean6 SEM basal peptide content was 7.86 0.27 pg/8 ml (n5 9 rats). R1–R45 recovery fractions.
B, Left and top, Ionized calcium–binding adapter molecule 1 (IBA-1)–positive profiles in control rats at 18 days and in rats with CIA at 7 days
and 18 days. Bottom right, Quantification of IBA-11 profiles in the dorsal horn of control rats and rats with CIA during CIA development
(n5 4–6 rats per group). Values are the mean6SEM. *5P, 0.05; **5P, 0.01; ***5P, 0.001 versus controls, by two-way analysis of var-
iance followed by Tukey’s test. ###5P, 0.001 versus basal levels, by two-way analysis of variance followed by Tukey’s test. Bar5 100 mm.
Figure 6. Intrathecal (IT) administration of a CGRP antagonist attenuates established mechanical hypersensitivity in CIA. A and B, Established
mechanical hypersensitivity (A) but not heat hypersensitivity (B) attenuated by 7-day intrathecal administration of CGRP8–37 (24 mg/day) (n5 9 rats
per group). C, Quantification of IBA-11 profiles in the L4 and L5 dorsal horns at 18 days (n5 4 rats per group). Values are the mean6 SEM.
**5P, 0.01; ***5P, 0.001 versus vehicle (Veh)–treated controls, by two-way repeated-measures analysis of variance followed by Tukey’s test
(A and B) or by Student’s t-test (C). PWT5 paw withdrawal threshold; PWLT5 paw withdrawal latency time (see Figure 5 for other definitions).
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hypersensitivity (allodynia) of the hind paw develops
concomitant with inflammatory cell infiltration in the
joint, activation of ankle joint nociceptors, and mild spi-
nal microgliosis, but not paw swelling. However, with
establishment of the disease, paw swelling and thermal
hypersensitivity (hyperalgesia) accompany mechanical
allodynia and, besides articular nociceptors, a significant
number of primary afferent neurons innervating tissues
outside the joint are activated. Furthermore, central
changes in the dorsal horn of the spinal cord are readily
detectable, including significant microgliosis and en-
hanced release of the pronociceptive peptide CGRP
from nociceptor central terminals. Such release of
CGRP is functionally relevant, as the delivery of a
CGRP receptor antagonist to the lumbar spinal cord
attenuates both mechanical allodynia and spinal micro-
gliosis. Thus, similar to other forms of chronic pain (23),
allodynia in CIA is likely to be maintained by a combina-
tion of central and peripheral mechanisms.
In the present study and in a previous study (5), we
observed the development of allodynia before the onset of
clinical signs of CIA in Lewis rats. Similarly, QB mice dis-
played allodynia before signs of arthritis in collagen anti-
body–induced arthritis (24). However, inDBA/1mice, CIA
allodynia developed along with the onset of clinical signs,
although that study largely assessed pain in association with
inflammation (4). These discrepancies highlight the impor-
tance of considering species and strain differences when
selecting themost appropriate RAmodel for pain studies.
We observed that a small percentage of sensory
neurons innervated the rat ankle joint, and their cell
bodies were located in the L4 and L5 DRGs, consistent
with previous findings in mice (25). These DRGs also
contain neurons innervating additional sites including
skin and muscle of the hind paw and the knee joint
(18,26,27). The number of sensory neurons innervating
the ankle joint was not altered by inflammation at any
stage of CIA, but the expression of both the nociceptive
peptide CGRP and the activation marker p-ERK
increased with the severity of disease, demonstrating
that CIA is associated not only with the activation of
these sensory neurons in the ankle joint, but also with
the activation of neurons innervating areas outside this
joint. For instance, the synovium of the ankle joint is
highly innervated by CGRP-expressing fibers, with
enhanced expression of CGRP reported in both the joint
and DRGs following adjuvant-induced arthritis (28).
Furthermore, as phosphorylation of ERK occurs in sen-
sory neurons following peripheral noxious stimulation,
the activation of this intracellular pathway is indicative
of nociceptive neuron activation (29,30). The increase in
nociceptive sensory neuron activation, together with the
development of allodynia and the exacerbation of the
disease reported herein, provide a mechanism that links
pain and inflammation. However, given that nociceptive
sensory neuron activation and the development of allo-
dynia occurred in the absence of paw swelling, our data
also suggest that pain hypersensitivity in the early phase
of CIA precedes macroscopic inflammation.
Joint afferents are highly responsive to mechanical
stimuli (6); thus, sensitization of these fibers likely drives
the central changes that underlie the early development
of mechanical allodynia during CIA. Nevertheless, even
though sensory neurons up-regulated nociceptive peptide
expression and displayed the presence of activation
markers in the early development of allodynia, their activ-
ity was not sufficient to detect increased CGRP peptide
release from their central terminals in the spinal dorsal
horn. It is possible that the sensitivity of our assay does
not allow for detection of small changes in CGRP content
that might have occurred. In any case, alongside CGRP,
the occurrence of glutamate and SP release from the cen-
tral terminals of primary afferent fibers in the dorsal horn
may contribute to behavioral allodynia (7). In order for
primary afferent enhanced input to become detectable in
our experimental system, the disease had to reach
advanced phases with evident inflammation and swelling
in the joints. Microglia appeared to be a more sensitive
indicator of spinal cord changes in CIA than increased
primary afferent input, as microgliosis was detected con-
comitant with the manifestation of allodynia and before
the onset of clinical signs.
Our data suggest that pain development in CIA
involves not only inflammation and changes in the joint,
but also alterations in central pain processing that are
dependent on pathologic inflammatory mechanisms.
Thus, subtle collagen-induced changes in the joint carti-
lage lead to an inflammatory milieu, including enhanced
cytokine and prostaglandin release, which results in the
sensitization of sensory neurons locally and mild micro-
gliosis in the spinal cord during the early phase of CIA
allodynia. Spinal microgliosis gradually increases with
escalating activation of nociceptive neurons by inflamma-
tory mediators in the joint with CIA. These mechanistic
data are particularly relevant in the context of CIA as a
model of RA, in view of the suggestion that activation of
central interleukin-1 signaling contributes to fatigue in
RA patients in whom the most likely source of this cyto-
kine are the microglia (31). Peripheral and central changes
grow in both incidence and significance in the later phases
of CIA allodynia and hyperalgesia, which are characterized
by an evident increase of noxious input from the periphery
to the spinal cord. In CIA, central changes such as micro-
gliosis and increased afferent input play a critical role in
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mediating allodynia as demonstrated by the analgesic
effect of a centrally delivered CGRP receptor antagonist.
Nevertheless, the small though significant microglial inhi-
bition through putative microglial CGRP receptors (32,33)
is not likely to be the primary mechanism of this antago-
nist, and attenuation of microgliosis is probably a reflection
of neuronal receptor blockade (34,35).
While we observed no changes in paw swelling fol-
lowing CGRP antagonist treatment (data not shown), spi-
nal mechanisms can regulate the extent of peripheral
inflammation in arthritis models. For example, spinal
manipulation of microglial signaling by inhibiting p38
MAPK reduces joint inflammation and disease progression
(36), with levels of spinal cytokines such as tumor necrosis
factor a (TNFa) regulating neuronal responses tomechan-
ical stimulation of the inflamed joint (37). It is relevant that
neutralization of TNFa in RA patients inhibits pain before
reducing inflammation in the joint (38), possibly through
inhibition of central sensitization. In our study, the mecha-
nisms underlying CIA thermal hyperalgesia, which devel-
ops concomitant with the onset of swelling and is unaltered
by a centrally delivered CGRP antagonist, remain to be
established. These mechanisms may reside peripherally
andmay arise from activation of different subsets of periph-
eral and spinal neurons (39). Indeed, while changes in
mechanical sensitivity are a major feature of central sensiti-
zation, peripheral sensitization plays a major role in the
alteration of heat sensation (13).
In conclusion, while RA results from immune-
mediated inflammation and damage to the joint, pain in
RA may not simply be the result of joint inflammation.
Indeed, pain may be experienced by patients before clinical
signs permit confirmation of the diagnosis (1). We suggest
that pain therapy in RA can be improved by developing
treatment strategies that take into account the association
of NSAIDs with molecules that stop central changes, for
example, inhibitors of microglial cell reactivity and CGRP
receptor antagonists or antibodies. Most of the currently
available CGRP antagonists, which were developed for
migraine, do not readily enter the central nervous system
(CNS) (40). However, whether CNS penetration is critical
for their antimigraine effect is still under debate (40). Our
study suggests that CNS-penetrating CGRP antagonists,
when available, may be effective analgesics in RA.
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